Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
Nexalin Technology (NASDAQ: NXL), a leader in Deep Intracranial Frequency Stimulation (DIFS™), has appointed Justin Van Fleet, CPA as Chief Financial Officer effective August 1, 2025. Van Fleet brings over 20 years of experience in public accounting and assurance services, most recently as Partner at Marcum LLP.
The appointment comes at a crucial time as Nexalin advances its Generation 2 and Generation 3 devices through FDA review. These non-invasive neurostimulation systems are designed to treat anxiety, depression, and other mental health conditions without drugs or surgery. Van Fleet will oversee the company's financial strategy, planning, and reporting functions during this critical growth phase.
Nexalin Technology (NASDAQ: NXL), leader nella Stimolazione Frequenziale Intracranica Profonda (DIFS™), ha nominato Justin Van Fleet, CPA come Chief Financial Officer a partire dal 1° agosto 2025. Van Fleet vanta oltre 20 anni di esperienza nella contabilità pubblica e nei servizi di revisione, più recentemente come Partner presso Marcum LLP.
La nomina arriva in un momento cruciale mentre Nexalin porta avanti la revisione FDA dei suoi dispositivi di seconda e terza generazione. Questi sistemi di neurostimolazione non invasiva sono progettati per trattare ansia, depressione e altre condizioni di salute mentale senza l'uso di farmaci o interventi chirurgici. Van Fleet supervisionerà la strategia finanziaria, la pianificazione e le funzioni di reporting dell'azienda in questa fase critica di crescita.
Nexalin Technology (NASDAQ: NXL), líder en Estimulación de Frecuencia Intracraneal Profunda (DIFS™), ha nombrado a Justin Van Fleet, CPA como Director Financiero, con efecto a partir del 1 de agosto de 2025. Van Fleet aporta más de 20 años de experiencia en contabilidad pública y servicios de aseguramiento, siendo su cargo más reciente el de Socio en Marcum LLP.
El nombramiento se produce en un momento crucial, ya que Nexalin avanza con la revisión de la FDA de sus dispositivos de segunda y tercera generación. Estos sistemas de neuroestimulación no invasiva están diseñados para tratar la ansiedad, la depresión y otras condiciones de salud mental sin medicamentos ni cirugía. Van Fleet supervisará la estrategia financiera, planificación y funciones de reporte de la empresa durante esta fase crítica de crecimiento.
Nexalin Technology (NASDAQ: NXL)는 심층 두개내 주파수 자극(DIFS™) 분야의 선도 기업으로, Justin Van Fleet, CPA를 2025년 8월 1일부로 최고재무책임자(CFO)로 임명했습니다. Van Fleet는 공공 회계 및 보증 서비스 분야에서 20년 이상의 경력을 보유하고 있으며, 최근에는 Marcum LLP의 파트너로 활동했습니다.
이번 임명은 Nexalin이 FDA 심사를 진행 중인 2세대 및 3세대 장치를 발전시키는 중요한 시기에 이루어졌습니다. 이 비침습적 신경 자극 시스템은 약물이나 수술 없이 불안, 우울증 및 기타 정신 건강 상태를 치료하도록 설계되었습니다. Van Fleet는 이 중요한 성장 단계에서 회사의 재무 전략, 기획 및 보고 기능을 총괄할 예정입니다.
Nexalin Technology (NASDAQ: NXL), leader dans la stimulation intracrânienne profonde par fréquence (DIFS™), a nommé Justin Van Fleet, CPA au poste de directeur financier, à compter du 1er août 2025. Van Fleet apporte plus de 20 ans d'expérience en comptabilité publique et services d'audit, ayant récemment été associé chez Marcum LLP.
Cette nomination intervient à un moment crucial alors que Nexalin fait avancer la révision par la FDA de ses dispositifs de deuxième et troisième génération. Ces systèmes de neurostimulation non invasifs sont conçus pour traiter l'anxiété, la dépression et d'autres troubles mentaux sans recours aux médicaments ou à la chirurgie. Van Fleet supervisera la stratégie financière, la planification et les fonctions de reporting de l'entreprise durant cette phase critique de croissance.
Nexalin Technology (NASDAQ: NXL), ein führendes Unternehmen im Bereich der Deep Intracranial Frequency Stimulation (DIFS™), hat Justin Van Fleet, CPA zum Chief Financial Officer mit Wirkung zum 1. August 2025 ernannt. Van Fleet bringt über 20 Jahre Erfahrung in der öffentlichen Buchhaltung und Prüfung mit, zuletzt als Partner bei Marcum LLP.
Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Nexalin seine Geräte der zweiten und dritten Generation durch die FDA-Prüfung bringt. Diese nicht-invasiven Neurostimulationssysteme sind zur Behandlung von Angstzuständen, Depressionen und anderen psychischen Erkrankungen ohne Medikamente oder Operationen konzipiert. Van Fleet wird die Finanzstrategie, Planung und Berichterstattung des Unternehmens in dieser wichtigen Wachstumsphase überwachen.
- Appointment of highly experienced CFO with 20+ years in public accounting and assurance services
- New CFO brings extensive expertise in IPOs, mergers, and complex financial transactions
- Strategic timing of appointment coincides with FDA review of Generation 2 and 3 devices
- Strong regulatory compliance background of new CFO supports upcoming product approvals
- Products still pending FDA approval with uncertain timeline
- Transition period may temporarily impact financial operations
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.
Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm’s assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He is widely recognized for his integrity, technical expertise, and strategic leadership, particularly in guiding companies through complex financial transactions such as IPOs, mergers, and other corporate events.
Throughout his career, Mr. Van Fleet has built a strong track record of developing robust financial systems, mentoring high-performing teams, and ensuring compliance with the highest professional and regulatory standards. He has worked directly with audit committees and boards to drive transparency, financial integrity, and operational excellence.
Mark White, CEO of Nexalin Technology, commented, “We are thrilled to welcome Justin to the Nexalin executive leadership team. His deep expertise in public accounting, regulatory compliance, and strategic financial management will be invaluable as we scale our operations and continue advancing our groundbreaking neurostimulation platform.”
“Nexalin is at a pivotal moment, with a highly differentiated technology platform that holds enormous promise for treating serious mental health conditions,” said Mr. Van Fleet. “I’m honored to join the team and contribute to the financial discipline and scalability needed to support Nexalin’s ambitious goals. This is an exciting time for the Company, and I look forward to helping drive its next phase of growth and innovation.”
As CFO, Mr. Van Fleet will oversee Nexalin’s financial strategy, planning, and reporting functions as the Company advances its innovative, non-invasive neurostimulation systems through regulatory review and into commercial readiness. Nexalin’s Generation 2 and Generation 3 devices, currently under FDA review, are designed to deliver deep-brain stimulation without drugs, surgery, or invasive procedures—offering a potential breakthrough in the treatment of anxiety, depression, and other chronic mental health conditions.
Mr. Van Fleet holds a Bachelor of Science in Accounting from SUNY New Paltz. He is a licensed CPA in both New York and New Jersey and is an active member of the AICPA, NYSSCPA, and NJCPA. He also serves as Treasurer and Asset Development Committee Member of the Community Foundation of South Jersey.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
Who is the new CFO of Nexalin Technology (NXL)?
What products does Nexalin Technology (NXL) have under FDA review?
What is Nexalin Technology's (NXL) main technology?
What experience does Justin Van Fleet bring to Nexalin (NXL)?
What will be Justin Van Fleet's role at Nexalin Technology (NXL)?
